RNA methylation into m1A era: a new regulation over T-cell function

Lin, Ping; Li, Guoping; Wu, Min

doi:10.1038/s41392-023-01360-4

Cited by 12 publications

(10 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oncolytic virotherapy is a promising avenue of immunotherapy that exerts its oncolytic effect by actively identifying and infecting tumor cells, replicating and eventually killing tumor cells with different regulatory mechanisms, such as inducing an innate immune response, but with immune exemption in normal cells (19). Although few viruses have currently been successfully developed into Food and Drug Administration-approved treatments for use in clinical regimens, the discovery of OVs can be traced back as far as the mid to late 19th century, when Dock (20) described a patient with myeloid leukemia who has suffered a spontaneous reduction of abnormal leukocyte counts after an influenza epidemic.…”

Section: Discussionmentioning

confidence: 99%

Tumor reduction after SARS‑CoV‑2 infection in a patient with lung cancer: A case report

Zhang,

Chen,

Sun

et al. 2024

Oncol Lett

View full text Add to dashboard Cite

Lung cancer is one of the most common malignancies worldwide. Since the global outbreak of the coronavirus disease 2019 (COVID-19) pandemic in 2020, the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on lung cancer has been extensively studied. Despite reports about SARS-CoV-2 infection inducing a significant increase in the number of medical visits for patients with cancer, the virus has also been reported to produce some unknown benefits. The present study reports the case of a patient with lung cancer whose tumor lesion was reduced in size after SARS-CoV-2 infection even though the therapeutic regimen remained unchanged. Although the mechanism involved is not yet understood, this case supports the novel idea of applying SARS-CoV-2 in oncolytic virotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Tumor reduction after SARS‑CoV‑2 infection in a patient with lung cancer: A case report

Zhang,

Chen,

Sun

et al. 2024

Oncol Lett

View full text Add to dashboard Cite

show abstract

Section: Crossing Cell Membrane Barriersmentioning

confidence: 99%

“…The reason for this probably arises from the enhanced interaction of positively charged GNPs with the negatively charged cell membrane. 14 After accumulation in lysosomes, positively charged GNPs could significantly disrupt lysosomal behaviors including enlargement, alkalinization and reduced motility. These changes affect the interaction between lysosomes and the cytoskeleton, which then induces the incompleteness and distribution of microtubules and microfilaments of the cytoskeleton (Fig.…”

Section: Gnps For Organelle Regulationmentioning

confidence: 99%

Gold nanoparticles cross cell-subcellular barriers for biological regulation

Zheng,

Qing,

Jia

et al. 2024

Inorg. Chem. Front.

View full text Add to dashboard Cite

show abstract

“…Firstly, they are capable of infecting and replicating selectively in tumor cells. Although the natural preference for cancer cells might vary among the different types of viruses, target accuracy can be improved by increasing their affinity and binding activity to overexpressed tumor cell surface receptors, or by focusing specific intracellular pathways and gene expression alterations in tumor cells [10]. Viral replication within cancer cells further results in a direct effect of cell lysis.…”

Section: Diverse Mechanisms Of Action Of Oncolytic Virusesmentioning

confidence: 99%

Promises of oncolytic viral therapy for adult and children with brain glioma

Patiño-García,

Alonso,

Gállego Pérez-Larraya

2023

Current Opinion in Oncology

View full text Add to dashboard Cite

Purpose of review The purpose of this review is to give an overview of early clinical studies addressing the safety and efficacy of oncolytic immunovirotherapy in adults and children with brain gliomas, and to highlight the extensive potential for the development of this therapeutic alternative. Recent findings The lack of curative treatments and poor prognosis of high-grade glioma patients warrants research on innovative therapeutic alternatives such as oncolytic immunovirotherapy. Engineered modified oncolytic viruses exert both a direct lytic effect on tumor cells and a specific antitumor immune response. Early clinical trials of different DNA and RNA oncolytic viruses, mainly Herpes Simplex Virus Type-1 and adenovirus based platforms, have consistently demonstrated an acceptable safety profile, hints of efficacy and the potential of this therapy to reshape the tumor microenvironment in both adult and pediatric patients with glioma, thus constituting the basis for the development of more advanced clinical trials. Summary The future landscape of oncolytic immunovirotherapy is still plenty of challenges and opportunities to enable its full therapeutic potential in both adult and children with brain gliomas.

show abstract

RNA methylation into m1A era: a new regulation over T-cell function

Cited by 12 publications

References 6 publications

Tumor reduction after SARS‑CoV‑2 infection in a patient with lung cancer: A case report

Tumor reduction after SARS‑CoV‑2 infection in a patient with lung cancer: A case report

Gold nanoparticles cross cell-subcellular barriers for biological regulation

Promises of oncolytic viral therapy for adult and children with brain glioma

Contact Info

Product

Resources

About